Articles tagged with Cancer Patients
Researchers at MUSC found that using FDA-approved small molecules can improve the potency and function of T cells in adoptive T cell therapy, making them more effective against melanoma. The treatment reduces regulatory T cells in the tumor microenvironment and enhances antitumor activity.
Dr. Daniel Von Hoff, a world-renowned expert in cancer therapies, is honored by Columbia University with a gold medal for his outstanding accomplishments in clinical medicine. This recognition marks the 250th anniversary of P&S, one of the nation's most accomplished medical schools.
Research by the German Cancer Research Center found that vitamin A deficiency can lead to a loss of dormant stem cells in the bone marrow, impairing the immune system. The study suggests that understanding how vitamin A regulates these stem cells could lead to new cancer treatments.
Researchers found that platelets release TGF-beta to suppress T cells and promote immune tolerance to certain cancers. Adding antiplatelet drugs like aspirin may improve adoptive T cell therapy against melanoma and other cancers.
High tumor PD-L1 expression after radiation therapy is associated with increased risk of head and neck cancer recurrence in HPV-negative patients. Researchers identified PD-L1 as a biomarker of poor outcomes, suggesting that combining radiation and a PD-1/PD-L1 inhibitor could improve survival rates.
A study published in The Lancet Gastroenterology & Hepatology found that patients with rectal cancer who undergo chemotherapy and radiation have excellent survival rates and low rates of cancer recurrence. These 'complete responders' may not benefit from surgery, raising questions about the safety of a watch-and-wait approach.
Around half of women with locally advanced cervical cancer experience symptoms like fatigue, insomnia, and hot flushes after treatment. Younger women are more likely to be affected. Research highlights the need for better recognition and treatment of these under-recognised symptoms.
A new analysis reveals heart failure patients experience worse survival rates than prostate cancer and breast cancer survivors, but better outcomes compared to lung cancer and ovarian cancer. The study highlights the continued burden of heart failure as a major public health concern.
A new study conducted at The Ohio State University Comprehensive Cancer Center found that more than half of breast cancer patients undergoing mastectomy lack necessary medical knowledge for high-quality decision-making about reconstructive surgery. Researchers emphasize the need for shared decision-making tools and patient-doctor commu...
Researchers at Florida State University have developed a statistical model that ranks chemotherapy treatment options for patients based on the gene expression profile of their tumor. The model takes into account both effectiveness and potential side effects, predicting a higher complete response rate for some subtypes of breast cancer.
A study conducted by Ohio State University researchers found that over half of breast cancer patients undergoing mastectomy lack necessary medical knowledge to make informed decisions about reconstructive surgery. Only 43% of patients demonstrated adequate understanding of reconstruction facts and made choices aligned with their prefer...
A study found that a decrease in circulating tumor cells with increased ALK gene copies is associated with longer progression-free survival in patients with non-small cell lung cancer treated with crizotinib. This biomarker may help predict treatment response and tailor therapies for individual patients.
A large study of African-American women found that those who drank seven or more drinks per week were 33% more likely to develop breast cancer than moderate drinkers. The study suggests that black women may benefit from limiting alcohol to reduce their risk, similar to white women.
The WorldQuant Initiative combines advanced molecular profiling technologies with quantitative methods to analyze genomic data, enabling the prediction of disease risk and outcomes. Researchers will leverage predictive tools to improve diagnosis and treatment for various illnesses.
A newly-created prognostic tool reliably predicts the recurrence of parathyroid cancer, allowing physicians to identify patients at highest risk. The tool is based on three key indicators: serum calcium level, age over 65, and tumor invasion into blood vessels.
Researchers found that most patients with intermediate-risk adenomas benefit from follow-up colonoscopies, reducing the risk of bowel cancer. However, a subgroup of patients may not require additional surveillance, potentially leading to cost savings for healthcare services.
Researchers will test drug Selumetinib on patients after endoscopic removal of stage I gastric cancer. The goal is to reverse pre-cancerous metaplasia and prevent cancer recurrence.
A study found that only 18 out of 47 cancer indications approved by the NHS Cancer Drugs Fund showed statistically significant benefits, with a median overall survival benefit of 3.2 months. The majority of drugs failed to show meaningful clinical benefits when considering quality of life and toxic side effects.
A new study published in Oncoimmunology suggests that kidney dysfunction in cancer patients can be triggered by the immune system's response to the tumor. Researchers identified neutrophils as a key player in this process, which can lead to impaired blood flow and inflammation in organs like the kidneys.
Four research teams will receive a grant of $250,000 over two years to support new research projects stemming from previous advances in cancer research. The award program aims to accelerate current research and development models to bring therapeutic benefits for cancer patients.
Children and adolescents have a higher risk of dying from second cancers compared to older adults. The study found that survival rates are significantly lower for second cancers in young patients, particularly those under age 40.
The American Society of Clinical Oncology will host its 53rd Annual Meeting, featuring more than 2,150 abstracts on various cancer topics. The meeting highlights recent breakthroughs in immunotherapy and precision medicine, with a focus on improving patient care and outcomes.
Researchers have developed a malaria protein-based drug that demonstrates promising results against chemotherapy-resistant bladder cancer. The new treatment showed a dramatic response to the malaria drug combo, resulting in an 80% survival rate among treated animals.
A new study by Yusheng Feng describes an algorithm that can predict the growth of cancerous tumors, helping medical professionals make informed decisions on treatment options. The algorithm takes into account various factors such as biological events and cell patterns to provide personalized predictions.
Analyzing four initial diagnostic protocols for asymptomatic microscopic hematuria, researchers found that combining renal ultrasound and cystoscopy was the most cost-effective approach. This method reduced incremental cancer detection costs by $53,810 per case.
Researchers are exploring immune cells that normally help the body but can hinder chemotherapy's effectiveness. By understanding how these cells interact, scientists hope to create targeted therapies to preserve chemotherapy's benefits while minimizing unwanted side effects.
The University of Kentucky has been awarded a $11.2 million grant to establish a new center for cancer and metabolism research. The Center for Cancer and Metabolism will focus on understanding the link between dysfunctional metabolism and cancer, with the goal of developing novel therapies.
A vaccine combining with high-dose chemotherapy improved glioblastoma patients' progression-free and overall survival. The vaccine targeted CMV antigen pp65, which is expressed in 90% of GBM tumors.
Researchers at MUSC found that Th17 cells can be expanded outside the body without losing effectiveness, providing a promising alternative to classic T cells used in adoptive immunotherapy. This breakthrough enables longer window periods for obtaining effective T cells via expansion outside the body.
A new study found that surgeons' recommendations against contralateral prophylactic mastectomy (CPM) did not increase the likelihood of patients seeking a second opinion or receiving surgery from a different surgeon. In fact, many patients were satisfied with their treatment despite no discussion about CPM. The study surveyed 1,140 pat...
Researchers found significant evidence that inhibiting protein TERT may aid in diagnosis and treatment of acral lentiginous melanoma (ALM). In laboratory experiments, over 75% of ALM cancer cells were affected by a drug that inhibits TERT.
A demo version of a new Pathology Atlas will be presented on April 2-5 at AACR17, offering information on human gene expression levels and their relationship with cancer patients' clinical outcomes. The atlas provides analysis on nearly 8,000 cancer patients across various major cancers.
A combination of a PARP inhibitor and a kinase inhibitor showed significant tumor shrinkage in 36% of patients with platinum-resistant ovarian cancer, a surprising improvement over solo PARP inhibitor treatment. The treatment was well-tolerated, with four patients discontinuing due to toxicity.
A study by the University of Pittsburgh Cancer Institute found that higher levels of tumor-associated immune cells and certain T cell types are associated with better response to immunotherapy. This could lead to more effective treatments for patients with recurrent head and neck cancer.
A new research project aims to integrate socio-economic data with cancer trial data, providing a broader perspective on treatment effectiveness. By combining this information, researchers can predict how socio-economic factors affect various treatments and shed light on the circumstances of cancer patients in clinical trials.
Researchers develop new technologies to precisely measure protein levels serving as tumor markers for personalized cancer treatment. This approach aims to predict tumor response to cancer therapeutics and match patients with the right drug.
A study found nearly half of young breast cancer patients in five states undergo preventive mastectomy to remove the unaffected breast. The proportion of women receiving this procedure increased significantly between 2004 and 2012, particularly among those under 45, with regional variations across states.
The ASCO and Cancer Care Ontario have updated their clinical practice guideline on brachytherapy for patients with prostate cancer. The new guidelines recommend different treatment options for patients with varying risk levels, including low-risk, intermediate-risk, and high-risk prostate cancer. For eligible patients, brachytherapy is...
Researchers at the University of Texas M. D. Anderson Cancer Center have identified arginine methyltransferase 1 (PRMT1) as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer with limited treatment options. PRMT1 plays a crucial role in tumor development and maintenance, and i...
The Georgia Cancer Center is part of a national effort to study cancer disparities across racial and ethnic groups. Researchers will collect data from 2,400 patients with early-onset cancers to better understand the underlying causes.
Scientists at Sylvester Comprehensive Cancer Center have found that p300 protein acts as a tumor suppressor, preventing myelodysplastic syndrome (MDS) from developing into acute myeloid leukemia (AML). Eliminating p300 in mice results in rapid leukemia development.
The article reviews current screening practice for melanoma in the US, highlighting risk groups and proposing full screening recommendations. The authors critically assess the USPSTF's 2016 Draft Recommendation Statement and propose evidence-based guidelines for screenings.
A study by UNC Lineberger Comprehensive Cancer Center found that women diagnosed with cancer during their childbearing years are at a higher risk of delivering preterm and having babies with low birth weight. The study identified potential risks for mothers who are cancer survivors, including a greater risk of cesarean section deliveries.
Researchers developed a computer program to diagnose cancer and locate tumors in blood samples, with an accuracy rate of 80% for early-stage cancers. The program uses molecular patterns in cancer DNA to identify the type and location of cancer.
A genome sequencing study for rare parathyroid carcinoma has identified mutations in known cancer-related genes and pathways, providing a clear view of genetic mechanisms involved. This in-depth characterization could lead to the first therapy options for patients with this deadly cancer.
Researchers at Washington State University developed a non-invasive filter-like device to isolate prostate cancer indicators from blood and urine, enabling doctors to track disease progression and treatment response. The technology uses biomarkers to capture tumor cells' genetic information, potentially predicting effective treatments.
Researchers at Ohio State University Wexner Medical Center correlated gene mutations with acute myeloid leukemia (AML) subgroups, identifying key mutational features and potentially important genetic differences among the subgroups. The study's findings may help guide mutation testing and treatment decisions in AML patients.
A new study found that adolescent and young adult cancer survivors often experience prolonged social difficulties, persisting even after treatment. Despite initial improvements in social functioning during the first year post-diagnosis, these patients tend to remain socially impaired relative to their cancer-free peers.
Researchers identified a series of proteins in blood plasma that signify cancer presence, offering a promising early detection method. The breakthrough discovery could enable regular blood tests to monitor treatment effectiveness and detect cancer recurrence.
Researchers have identified pre-metastatic niches that prepare the ground for tumor cells to survive before invading other organs. Understanding this phenomenon could lead to new diagnostic and therapeutic tools to prevent cancer-related death.
A new study led by researchers at Mount Sinai Hospital found that early referrals to palliative care reduced healthcare utilization and increased use of support services after discharge. The study also showed significant improvements in 30-day readmission rates, hospice referral, and chemotherapy receipt.
The American Society of Clinical Oncology has released a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer. The guideline offers evidence-based recommendations for four levels of resource settings, providing guidance to health care providers worldwide.
The ABC Global Alliance, led by ESO, has launched a call-to-action to improve and extend the lives of patients with advanced breast cancer by 2025. The initiative outlines key gaps and actionable imperatives across patient care, societal support, and scientific investment for mBC.
African Americans and American Indians received less likely to receive potentially curative treatments for stage I non-small cell lung cancer (NSCLC), while Asian/Pacific Islanders had better survival rates. Patients who received definitive treatment had improved survival rates, regardless of race, age, or gender.
A clinical trial shows that combining chemotherapy drug temozolomide with radiation therapy extends survival by two months in older patients with glioblastoma. The treatment also improves survival for 45% of participants, linked to a molecular marker indicating active DNA repair mechanisms.
A new computational method allows researchers to quickly compute immune cell infiltration and calculate personal immune response profiles for thousands of patients. The study reveals complex interactions between different immune cell types in the tumor microenvironment play meaningful roles in patient survival.
Patients cured of Hodgkin lymphoma are at a significantly increased risk of developing a second type of cancer, particularly if they have a family history of the disease. The risk remains high even 30 years after treatment, and is higher in those with specific genetic markers or a history of certain cancers.
Researchers are exploring parallels between military counter-insurgency tactics and cancer treatment, focusing on targeted therapies that harness the patient's own resources. By adopting an intelligence-led approach, clinicians can adapt treatment strategies to tackle evolving tumour genetic codes.
A free lung cancer screening in the Augusta area found more than double the cancer rate of previous screenings, with 3% of participants diagnosed with lung cancer. The majority of cases were caught early, with a 90% overall survival rate for those detected before symptoms appeared.
Researchers have developed a novel DNA barcode technology to improve the sensitivity of genomic sequencing. SiMSen-Seq, a technique that reduces error rates to 1 in 10,000, enables earlier detection of cancer recurrence and potential relapses.